Back to News
Market Impact: 0.25

ETF Fundamental Report for IWM

IWMNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechMarket Technicals & Flows
ETF Fundamental Report for IWM

Validea's fundamental report indicates that the iShares Russell 2000 ETF (IWM) is a Mid-Cap Value ETF with its largest sector allocation in Services and industry allocation in Biotechnology & Drugs; factor scores reveal moderate exposure to Value (57) and low exposure to Momentum (39), Quality (7), and Low Volatility (14).

Analysis

Validea's fundamental report on the iShares Russell 2000 ETF (IWM) identifies it as a Mid-Cap Value ETF, with its largest sector concentration in Services and its most significant industry exposure in Biotechnology & Drugs. According to the factor analysis, IWM scores 57 out of 99 for Value, indicating a moderate alignment with value characteristics. However, its exposure to other factors is markedly weak: Momentum scores 39, Quality scores a very low 7, and Low Volatility scores 14. This factor profile suggests that while IWM provides some representation of undervalued mid-cap companies, it does not significantly overweight stocks exhibiting strong recent performance, high financial quality, or historically low price volatility. The notably low Quality score of 7 implies that, on average, the underlying constituents of the ETF do not demonstrate robust financial health metrics, a key consideration for investors prioritizing fundamental strength.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

IWM0.00
NDAQ0.00

Key Decisions for Investors

  • Investors should acknowledge IWM's moderate value orientation (Value score: 57) but must carefully consider its exceptionally low Quality score (7), which suggests a potential need for complementary strategies if financial robustness of underlying holdings is a priority.
  • Given the low scores for Momentum (39) and Low Volatility (14), IWM is unlikely to satisfy investors specifically seeking these factor exposures; alternative or supplementary investments may be required to achieve such tilts.
  • The significant allocation to the Biotechnology & Drugs industry warrants close monitoring due to the sector-specific volatility and risk profile, which could impact IWM's performance independently of broader market movements.